Revance Therapeutics, Inc.
Revance Therapeutics, Inc., a leading biotechnology company headquartered in the United States, focuses on innovative aesthetic and therapeutic solutions. Founded in 2011, Revance has made significant strides in the industry, particularly with its proprietary DaxibotulinumtoxinA injection, which offers a unique, long-lasting alternative to traditional neuromodulators. With a strong presence in the aesthetic and therapeutic sectors, Revance is committed to advancing patient care through its cutting-edge products. The company has achieved notable milestones, including successful clinical trials and regulatory approvals, positioning itself as a key player in the competitive landscape of biotechnology. Revance's dedication to innovation and quality sets it apart, making it a trusted name in the field.
DitchCarbon Score
How does Revance Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Revance Therapeutics, Inc.'s score of 20 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Revance Therapeutics, Inc.'s reported carbon emissions
Revance Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives. Without specific emissions figures or commitments, it is challenging to assess their climate impact or sustainability efforts. However, as a company operating in the biopharmaceutical sector, Revance is likely aware of the growing importance of addressing climate change and may be exploring strategies to align with industry standards. As the landscape of corporate climate commitments evolves, it will be essential for Revance to establish clear targets and transparency in their environmental practices to meet stakeholder expectations and contribute to global sustainability goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Revance Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
